Comparative PK/PD of Single-Dose THDB0206 at Different Injection Sites

Inclusion criteria

• Aged ≥18 and ≤40 years at screening.
• Body mass index (BMI) ≥18 kg/m² and <25 kg/m² at screening; body weight ≥50 kg for males and ≥45 kg for females at screening.
• At screening, 75 g oral glucose tolerance test (OGTT): fasting venous plasma glucose <6.1 mmol/L and 2-hour post-load venous plasma glucose <7.8 mmol/L.
• Glycated hemoglobin (HbA1c) ≤6.1% at screening.

Exclusion criteria

• Known or suspected hypersensitivity to the investigational product or related products, or a history of severe allergies to drugs or foods.
• Insulin release test at screening considered abnormal with clinical significance in the investigator's judgment.
• Increased risk of thromboembolism, such as known coagulation disorders, (family) history of thrombosis, or relevant arrhythmias (e.g., paroxysmal atrial fibrillation).
• In the investigator's judgment, a history of alcohol dependence or drug/chemical substance abuse; or positive results on drug screening/breath alcohol testing at screening; or alcohol consumption exceeding 21 units per week (male subjects) or 14 units per week (female subjects).
• Subjects who smoked on average more than 5 cigarettes per day within 1 year prior to screening and are unwilling to abstain from smoking during the study.
• Donation of blood or plasma within the past month, or donation of more than 300 mL of blood within 3 months prior to screening.